Spermidine has been hyped as a brain-protecting supplement on the strength of autophagy research and animal studies. The SmartAge trial put it to a rigorous test in 100 older adults with subjective cognitive decline, giving about 0.9 mg per day for 12 months. The primary memory outcome did not beat placebo (difference -0.03; P = .47), and secondary outcomes were also null. Exploratory hints on inflammation and verbal memory remain unconfirmed. Here is what the result means for anyone considering a spermidine supplement, and where the study's limits lie.
This page is available in